santa cruz biotechnology, inc.
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benvenuto! Visualizza carrello Quick Order
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
eRF Anticorpi
Translation is carried out by the ribosome and several associated protein factors through three consecutive steps: initiation, elongation and termination. Termination of protein synthesis takes place when the ribosomal A site is occupied simultaneously by one of three stop codons and by a class 1 translation termination factor. In eukaryotes, this termination factor is the eukaryotic release factor 1 (eRF1), a protein that promotes hydrolysis of the last peptidyl-tRNA on the ribosome. eRF1 activity is stimulated by the association with the GTP-binding protein eRF3. eRF1 forms a quaternary complex with eRF3, GTP and the ribosome. Subunits of eRF3 are eRF3b and eRF3a, which belong to the GTP-binding elongation factor family and are involved in the regulation of cell growth, specifically via control of translation termination.
eRF Anticorpi
eRF specific siRNA, shRNA Plasmid and shRNA Lentiviral Particles gene silencers include:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
